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Abstract: The pathophysiology of migraine is not completely understood and continues to be investigated. The complex-
ity of interactions taking place in the sensory neuronal network with the mediation of all different neurotransmitters in-
volved gives the measure of the extreme difficulty connected with the knowledge of migraine pathogenesis and in particu-
lar of its cardinal sign. Neuronal components are relevant in migraine pathophysiology: there could be a generalized inter-
ictal abnormal excitability of the cerebral cortex in migraine, possibly favoring the occurrence of spreading depression 
with consequent activation of the trigeminal system. Many theories have been formulated in these last sixty years about 
the pathogenesis of migraine and other forms of primary headache, but the problem is still far to be fully clarified. The 
present review is focused on the description of different theories on the migraine pathogenesis. 
This review is dedicated to the memory of Prof. Alfredo Bianchi. 
INTRODUCTION 
  Migraine is a neurological syndrome characterized by 
altered perceptions, headaches, and nausea. Migraine is an 
invalidating disturbance largely spread (>12%) in the world 
population, having the form of an autonomous disease, as 
well secondary or indirect (2-3%), in this last case being 
only a pathologic symptom of different etiologies. The last 
headache classification, published in 2004, divides, respec-
tively, in four and ten groups, with relative subtypes, the 
primary and secondary headaches [1]. The typical migraine 
headache is unilateral, throbbing, moderate to severe. The 
pain may be bilateral at the onset or start on one side and 
become generalized, and usually alternates sides from one 
attack to the next. The pain peaks and then subsides, and 
usually lasts between 4 and 72 hours in adults and 1 and 48 
hours in children. The frequency of attacks is extremely 
variable, from a few in a lifetime to several times a week, 
and the average migraineur experiences from one to three 
headaches a month. The head pain varies greatly in intensity. 
  The pain of migraine is invariably accompanied by other 
features. Nausea occurs in almost 90 percent of patients, 
while vomiting occurs in about one third of patients. Many 
patients experience sensory hyperexcitability manifested by 
photophobia, phonophobia, osmophobia and seek a dark and 
quiet room. Blurred vision, nasal stuffiness, diarrhea, polyu-
ria, pallor or sweating may be noted during the headache 
phase. There may be localized edema of the scalp or face, 
scalp tenderness, prominence of a vein or artery in the tem-
ple, or stiffness and tenderness of the neck. Impairment of 
concentration and mood are common. Lightheadedness, 
rather than true vertigo and a feeling of faintness may occur 
[1]. We will concentrate our attention on the migraine patho-
genesis, taking in consideration involved afferent and effer-
ent functions of primary and secondary neurons, with rela-
tive neurotransmitters. 
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GLUTAMATE AND MIGRAINE  
  Afferent fibres of nociceptive primary neurons are ending 
in the superficial part of the ipsilateral spinal horn after hav-
ing contracted synaptic connections with the second order 
excitatory glutamatergic neurons. Glutamate is able to acti-
vate different types of receptors, ionotropic and me-
tabotropic, located centrally as well in the periphery. AMPA 
and kainate receptors, ionotropic, provoke excitatory post-
synaptic potentials (EPSPs) having a rapid onset and a short 
duration (few ms). NMDA receptors, also ionotropic, induce 
slower EPSPs, lasting about 100 ms. Metabotropic glutamate 
receptors, called mGluR, play an important modulating role 
on the hyperalgesic response; for some of them, like mGlu 4 
and mGlu 6-8, positive, for others (mGlu1 and mGlu 5) 
negative. They activate, through G-proteins, intracellular 
metabolic chains. The phosphorilation of intracellular sub-
strates like ionic channels is able to modulate different 
phases of the synaptic transmission and the activation of 
mGlu 5 can increase the sensitivity of ionotropic receptors 
also for the glutamate itself. All different glutamate receptors 
seem to be involved in the phenomenon of hyperalgesia 
(lowering of nociceptors threshold and intensity), bringing to 
the elevation of pain induced by noxious stimuli and chronic 
pain mechanisms. Central sensitization phenomena to which 
the hyperalgesia is connected seem to depend significantly 
from the NMDA and mGluR receptors activation operated 
by glutamate [2]. 
  The spreading depression (SD), characterized by a mas-
sive failure of ion homeostasis associated to a transient ces-
sation of neuronal function, and believed to be involved in 
migraine pathogenesis, requires the release of glutamate; 
NMDA receptors play a crucial role in the propagation of 
this process. In isolated layers of murine brain enthorinal 
cortex slices containing the NMDA–receptor-mediated com-
ponent of extracellularly recorded field EPSPs, the electrical 
stimulation performed in order to elicit spontaneous SD , in 
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tagonist, was nearly unable to produce the occurrence of SD 
[3].  
  In anaesthetised cats, recordings of the trigemino-cervical 
complex activity evoked by electrical stimulation of superior 
sagittal sinus, in cells activated by L-glutamate, showed that 
CGRP receptor antagonists alpha-CGRP and BIBN4096BS, 
given by microiontophoresis onto neurons in the trigemi-
movascular complex or intravenously, significantly inhibit 
the evoked activity. Data obtained suggest that there are non-
presynaptic CGRP receptors in the trigeminocervical com-
plex that can be inhibited by CGRP receptor blockade and 
therefore that a CGRP receptor antagonist could be effective 
in the acute treatment of migraine and cluster headache [4]. 
An in vitro study in human embryonic kidney has shown that 
a selective and non-competitive GLU-K5 antagonist is able 
to inhibit l-glutamate and domoate- evoked currents blocking 
the kainate subtype of glutamatergic receptors [5]. Nocicep-
tive spinal neurons present a high degree of plasticity re-
vealed by the increased intensity and duration of neuronal 
discharges after repeated injuries and prolonged activation of 
C fibres. Neuronal plasticity and Long Term Potentiation 
(LTP) processes could be responsible for chronic pain mani-
festations which are at the basis of chronic migraine. In the 
LTP genesis is fundamental the NMDA receptor activation 
which induces a raise of intracellular Ca
++ concentrations 
stimulating NO-synthase (NOS), a Ca
++ - calmodulin – de-
pendent enzyme, able to provoke an increased NO forma-
tion. This last compound is active at the level where it is 
produced as well as in the extracellular space, reached by 
diffusion, and in this place stimulates the guanilato-cyclase 
of adjacent neuronal endings, provoking a further release of 
glutamate. 
  The repeated and intense stimulation of NMDA receptors 
occurring during migraine attacks and the consequent onset 
of sensitization could explain the progressive worsening 
leading from a form of headache showing many free inter-
vals to the daily inter-critical chronic headache which 
obliges the patient to daily administrations of analgesics un-
der the risk of abuse. 
  NMDA antagonists like ketamine, given subcutaneously 
or intravenously by daily continuous infusions, have been 
assayed in order to avoid the chronic evolution and the ad-
diction toward analgesics, frequently observed in these con-
ditions [6].  
  A rational perspective for the future is represented by 
antagonists and modulators of ionotropic or metabotropic 
glutamate receptors which could be therapeutically effica-
cious in the treatment of chronic forms of migraine and other 
types of primary headache. It has been recently shown that 
the glutamatergig system is implicated in cortical spreading 
depression, trigemino-vascular activation and central sensiti-
zation in preclinical models of migraine, and in the clinic [7].  
OPIOID PEPTIDES AND MIGRAINE 
  The transmission of nociceptive messages from afferent 
primary fibres as well as the activity of spinal nociceptive 
neurons are modulated by presynaptic and postsynaptic 
mechanisms, mediated through different subtypes of spinal 
interneurons (gabaergic, glycinergic and enkephalinergic). 
  The first control station of painful afferences is the ge-
latinous substance (GS) located in the spinal grey posterior 
horn. GS is rich of opioid peptides (enkephalins and dynor-
phins) and, of course, of opioid receptors mu and k as well as 
of theirs interneurons, which selectively inhibit neurotrans-
mitters release from A-delta and C efferent fibres, so making 
an access gate for painful afferences. Opioid peptides exert a 
prevalent inhibiting effect on neuronal activity due to the 
opening of K
+ membrane channels, operated by mu and delta 
receptors, or to the closing of Ca
++ channels (k receptors). 
  Spinal nociceptive circuits and especially enkephaliner-
gic neurons are under the control of neuronal systems de-
scending from the brainstem able to exert facilitating or in-
hibiting effects and therefore playing an important role in the 
regulation of nociceptive reflexes and pain perception.  
  The grey periaqueductal substance (PAG), the raphe 
magnum nucleus (NRM), reticular paragigantocellular 
(NRPG) and magnocellular (NRMC) nuclei form all together 
the inhibitory descending system. PAG neurons project upon 
NRM, where arise descending serotoninergic fibres and 
NRPG as well as NRMC, and from this last structures take 
origin noradrenergic descending fibres, directed, as the sero-
toninergic fibres, to the spinal cord. Serotoninergic and 
noradrenergic pathways activate spinal enkephalinergic in-
terneurons, negatively modulating, through a presynaptic 
inhibition, the transmission of the nociceptive message. In 
this way opioid agonists, like morphine, fentanyl, pentazo-
cine , buprenorphine and others,exert their analgesic effect. 
  Though the opioid system has received not a major con-
sideration in the study of migraine pathophysiology, its in-
volvement can be postulated. As far as morphine is con-
cerned, according to several observations, it seems that this 
drug could worsen rather than attenuate the migraine pain. 
  In United States only butorphanol has been employed by 
intranasal route in the therapy of very severe migraine at-
tacks. It has been observed the absence of interaction be-
tween butorphanol and sumatriptan also when the admini-
stration of these two drugs is practised closely in time [8].  
  Recently it has been found that the gene codifying for mu 
receptors is polymorphous and this peculiarity could explain 
the individual variability to stimuli generating pain. Since 
migraine is very likely a disorder characterized by a variable 
threshold and a multiform pathogenesis, both characters be-
ing tied to different genes, it is not possible to exclude that 
the mu opioid receptor could represent one the factors con-
tributing to the determination of migraine threshold and on 
this basis it will be rational to address in such direction fu-
ture studies on migraine genetic aspects, in order to evaluate 
precisely the eventual involvement of all sub-types of opioid 
receptors.  
  Opioid analgesics appear to be generally inefficacious in 
the management of chronic daily headache. The study of 
pathophysiological models of opioidergic pathways for mi-
graine and chronic daily headache, as well as for neural plas-
ticity in the context of neuropathic pain states, have allowed 
the concept of chronic daily headache as a neuropathic pain 
syndrome [9]. 
SEROTONINERGIC RECEPTORS AND MIGRAINE 
  The experimental research in animal models has given in 
these last years the opportunity to obtain a large amount of 
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pathogenesis of migraine and cluster headache. Although the 
knowledge of complex pathogenetic factors involved at the 
level of the central nervous system in the production of the 
migraine attack is still full of gaps, we dispose of a consider-
able information on peripheral factors presumably responsi-
ble of pain mechanisms in migraine and other types of pri-
mary headache. 
  The brain is not provided with pain sensitive endings, 
while meninges are rich of nociceptors. The ophthalmic 
branch of trigeminal nerve reaches extra-cerebral vessels at 
the level of meninges (dura mater, arachnoid and pia mater) 
which receive peripheral fibres coming from pseudo-
unipolar neurons present in the trigeminal ganglion. These 
fibres form the neuroanatomical circuit known as trigemino-
vascular system, forwarding stimuli received from afferent 
peripheral endings to the trigeminal caudalis nucleus and to 
other brainstem nuclei as superior salivatorius nucleus. Ac-
cording to Edvinsson and Goadsby [10], through this last 
nucleus could be activated an afferent cholinergic pathway 
of the seventh cranial nerve, with the release at the menin-
geal level of Vasoactive Intestinal Peptide (VIP), able to 
provoke further vasodilatation and hyperactivation of tri-
geminal fibres An important role is attributed to parasympa-
thetic pathways in migraine pathogenesis specially in order 
to explain some symptoms like tearing, conjunctival blood 
injection and rhinorrhea observed frequently in patients suf-
fering from cluster headache.  
  The trigemino-vascular system, therefore, with its differ-
ent components, represents one of the most important anat-
omic and functional areas for the study of migraine patho-
physiology.  
  The characterization of 5-HT receptors within trigeminal 
sensory neurons has deeply improved the knowledge about 
the pathogenesis and treatment of migraine; among them 5-
HT1B are located in the smooth muscle of meningeal extrac-
ranial vessels, 5-HT1D in trigeminal sensory endings [11] 
and 5-HT1F at the level of trigeminal nucleus caudalis, as 
well as peripherally in trigeminal gangliar endings [12]. The 
stimulation of first two sub-types of 5-HT receptors inhibits 
the release of vasoactive peptides like CGRP and pain 
transmitter peptides like substance P and neurokinin A [13]. 
The peptides are involved in the dural plasma extravasation 
provoked by the neurogenic inflammation due, in experi-
mental animal models, to the depolarization following the 
electric stimulation of peripheral trigeminal fibres. In these 
models the release of CGRP caused by the activation of tri-
geminal fibres leads to a further dilatation of meningeal ves-
sels, wich, in turn, brings about the hyperactivation of central 
and peripheral trigeminal endings responsible of pain (Fig. 
1). These pathophysiological mechanisms,. discovered by 
Moskowitz [14], could be, in the rat, at the basis of migraine 
pain, but this hypothesis has been not yet definitely validated 
in the man, though it has received a strong support from the 
significant therapeutical activity exerted by triptans toward 
the primary headache pain. Actually it is well known that 
sumatriptan inhibits the CGRP gene transcription in trigemi-
nal sensory neurons, but it has not been clarified yet whether 
this action is mediated only by 5-HT1D or also by 5-HT1B 
receptors, the last having been isolated, as the relative 
RNAm, in human trigeminal gangliar neurons, in absence of 
an histochemical demonstration of this receptor transporta-
tion at the level of central and peripheral endings, as it hap-
pens for 5-HT1D [12], which is present also at the level of 
the solitary tract nucleus. In this site, believed to be involved 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Role of the trigeminal neuron in the migraine attack. 
Attack eliciting factors at the sub-cortical level provoke dilatation of cranial vessels with the activation of trigeminal sensory afferent endings 
and a consequent neurogenic inflammation process, due to the release of CGRP and SP or NK-A. 
BK: bradykinin; NO: nitric oxide; CGRP: calcitonin gene-related peptide; SP: substance P; NK-A: neurokinin A.  Migraine  The Open Neurology Journal, 2009, Volume 3    67 
in the pathogenesis of some migraine symptoms like nausea 
and vomiting for its connections with the autonomous nerv-
ous system, arrive numerous trigeminal afferent fibres and, 
therefore, the therapeutic activity of triptans on the above 
mentioned symptoms, associated to the analgesic effect, 
could be exerted either directly on the solitary tract nucleus 
or indirectly, as a consequence of the reduced activation of 
the trigeminal nociceptive system.  
  Another indirect proof of the possible application to hu-
mans of the neurogenic inflammation theory of Moskowitz 
seems to reside in some observations made by Goadsby et al. 
[15], according to them CGRP levels increase in the external 
jugular vein blood during migraine attacks. 
  On the other hand, the same authors showed the correla-
tion existing between the decrease of blood CGRP levels and 
therapeutic efficacy of triptans. Through their agonist activ-
ity on 5-HT1 B-D-F receptors these drugs could inhibit at the 
presynaptic level the release of neuropeptides able to pro-
voke either intracranial vasodilatation or pain characteristic 
of migraine and related to the stimulation of primary tri-
geminal nociceptive neurons, which represent the first step 
in the pain transmission. These receptors, in turn, activate, 
through their central endings, second order nociceptive neu-
rons at the level of brainstem, in the trigeminal nucleus cau-
dalis where also 5-HT1 F receptors are located as well as at 
peripheral endings of gangliar trigeminal neurons in which 
they could have a function analogous to that of 5-HT1 D 
receptors [12]. 
  Antagonists of 5-HT1 F like LY 3334370 inhibit selec-
tively, in anesthetized rats, the activation produced by the 
electrical stimulation of dura mater and of second order neu-
rons in trigeminal nucleus caudalis, in this way blocking the 
transmission of nociceptive inputs to central areas [16]. 
  Since many triptans show to be provided with a 5-HT1 F 
agonist activity it is possible to hypothesize that their thera-
peutic efficacy be partially due to the ability by them pos-
sessed to activate this sub-type of 5-HT1 receptors either at 
peripheral levels or, perhaps more likely, centrally, in corre-
spondence of the trigeminal nucleus caudalis [16,17].  
  Preclinical investigations in rats have shown that anti-
migraine triptan drugs exert their effect not only by blocking 
the neuropeptide neurotransmitter release from sensory nerve 
terminals and directly constricting blood vessel smooth mus-
cles, because also the modulation of glutamate and NO re-
lease by them operated can contribute to their activity 
[18,19] . The majority of 5-HT1B, 5-HT1D and 5-HT1F are 
co-located with glutamate receptors being glutamate positive 
,as it is possible to demonstrate using techniques of immu-
nohistochemical staining [20]. According to Levy et al. [21], 
triptans analgesic action is exerted through presynaptic 5-
HT1B-D receptors in the dorsal horn by blocking the synap-
tic transmission between axon terminals of the trigeminovas-
cular neurons and cell bodies of their central counterparts. 
On this basis the analgesic action of triptans can be attained 
specifically in presence and not in the absence of central 
sensitization. The early treatment with triptan drugs provides 
a powerful means of preventing the initiation of central sen-
sitization triggered by chemical stimulation of menigeal no-
ciceptors [22]. An important site of action for triptan anti-
migraine drugs is the nucleus tractus solitarius where tri-
geminovascular activation triggers nausea and vomiting, 
frequently associated with pain in the migraine attack [23]. 
GABAERGIC RECEPTORS AND MIGRAINE 
 Among  receptors with a prevailing inhibitory activity an 
important role is played by GABA receptors, in particular in 
the neurogenic inflammation process, as it has been proven 
in animal experimental models using valproate [24], an anti-
convulsant drug currently used in the preventative treatment 
of migraine, also assayed as a symptomatic of second order 
in the therapy of cluster headache [25]. Good results have 
given in the treatment of primary headache also more recent 
anticonvulsant like gabapentin, lamotrigine, tiagabine, topi-
ramate and others [26, 27].  
  GABA-A receptors are located in trigeminal sensory neu-
rons. Valproate is provided with two mechanisms of action, 
being able to inhibit GABA-transaminase, which causes 
GABA degradation and, at the same time, to activate glu-
tamic - decarboxylase, that induces GABA synthesis. There-
fore, following its administration, GABA extracellular con-
centrations in the proximity of GABAergic endings are in-
creased [28].  
  Valproate, in experimental animal models, blocks dural 
plasmatic extravasation induced by neurogenic inflammation 
due either to the electric stimulation of trigeminal fibres or to 
the intravenous administration of substance P. For this aspect 
preclinical data have been obtained later than clinical evi-
dences, when the use of valproate in migraine therapy was 
already consolidated, but anyhow they bring a strong support 
to the hypothesis that the activation of trigeminal sensory 
neurons is an initial step in the neurogenic inflammation 
process and in the pathogenesis of primary headache pain. 
  About GABA-B receptors they have also been implicated 
with migraine pathogenetic mechanisms. The coupling be-
tween GABA and GABA-B receptors induces the activation 
of a specific Gi-protein, exerting an inhibitory effect on the 
enzyme adenylate-cyclase with the reduction of intracellular 
cAMP levels and decreased phosphorylation: Consequently 
it is produced a functional block of voltage-dependent Ca
++ 
channels involved in the neurotransmitter release. GABA-B 
agonists, as baclofen, then, may negatively modulate, trough 
these mechanisms, the release of many neurotransmitters, 
GABA included. Baclofen indeed has shown to inhibit the 
activation of trigemino-vascular system at the level of the 
spinal trigeminal caudatus nucleus and therefore to be fur-
nished of a distinguished anti-nociceptive activity, observed 
in many clinical trials on patients suffering from migraine or 
cluster headache [29,30]. 
CANNABINOID, VANILLOID AND PAR RECEP-
TORS RELATED DRUGS AND MIGRAINE  
  At the level of peripheral and central endings of primary 
sensory neurons are present also cannabinoid, vanilloid and 
PAR receptors, characterized only few years ago (Table 1), 
which seem to play an important role in pain pathophysiol-
ogy Endocannabinoids (anandamide and 2-acyl-glycerol , 
having a lipidic structure, derive, like eicosanoids and Plate-
let Activating Factor (PAF), from membrane phospholipids 
and their pharmacodynamic profile is similar to that of the 
Cannabis active principle delta-9-tetrahydrocannabinol and 
other natural and synthetic cannabinoids. The synthesis of 68     The Open Neurology Journal, 2009, Volume 3  Salomone et al. 
anandamide is regulated by the phospholipase D, while an-
other intracellular enzyme, the Fatty Acid Amide Hydrolase 
(FAAH) is responsible of its degradation, followed by the 
reassumption of its constituents in phospholipids [31]. Dif-
ferently from neurotransmitters and neuropeptides which are 
continuously synthesized and then stored in special deposit 
sites, from where they are released in consequence of the 
excitation of nerve endings, endogenous cannabinoids are 
produced from endothelial cells, macrophages and peripheral 
cells only when their holocrine-paracrine function has to be 
developed, during the inflammation process and in all condi-
tions of cellular injury [32, 33]. 
  Once released in the extracellular place, anandamide ac-
tivates, at nanomolar concentrations,its own receptors de-
fined cannabinergic (CB) and generally distinguished in CB-
1 and CB-2, while, at micromolar concentrations [34], stimu-
lates vanilloid receptors (VR-1).  
  CB receptors of both types are coupled, through a Gi- 
protein, with the adenilate cyclase [35]. CB-1s mediate anal-
gesic effects of anandamide either peripherally or centrally; 
CB-2s, present in lymphocytes B and natural killer, seem 
able to produce, when activated, an anti-inflammatory ac-
tion. 
  Anandamide (AEA) thus exerts centrally and peripher-
ally an inhibitory effect on the pain, due to the activation not 
only of encephalic and spinal (10
th lamina) CB receptors, as 
in the PAG [36], but also of peripheral sensory neurons [37], 
in particular at the level of central peptidergic capsaicin-
sensitive endings, containing CGRP and substance P, where 
their release is reduced [38].  
  Hohmann and Herkenham [39] have demonstrated, by 
histochemical techniques, the presence of CB-1 also in the 
peripheral endings. Calignano et al. [40] showed that CB-1 
agonists, like WIN552122, when applied on the skin, are 
able to reduce the nociceptive activity of formalin. 
  After a protracted and intense noxious stimulation, suffi-
cient to provoke an inflammatory reaction, central and pe-
ripheral neuronal excitability is significantly increased until 
the onset of hyperalgesia and pain production by normally 
innocuous events (allodynia). Cannabinoids, in animal ex-
perimental models, antagonize either hyperalgesia or allo-
dynia [41-43]. On the other hand, CB-1 antagonists, like 
SR141716A, decrease the activation threshold, increasing 
the response to mechanic and thermic stimuli. 
  Therefore, it may happen that, following repeated or pro-
tracted noxious stimulations, as after a traumatic injury or in 
course of inflammation, endocannibanoid levels appear in-
creased either peripherally or centrally, for example in the 
PAG, while at the same time a sensitization of CB-1 recep-
tors is observed. Thus experimental data seem to demon-
strate the central role of endocannibanoids in pain pathways, 
disclosing the perspective of a possible interaction on these 
new targets in the treatment of various clinical forms of pain. 
  Anandamide, therefore, activates, respectively at nano-
molar and micromolar concentrations, CBs and VR-1 recep-
tors, these last capsaicin-sensitive [34], with opposite effects 
on pain, toward which it exerts a dual activity, stimulatory or 
inhibitory, so assuming in the regulation of this function, a 
balancing role. Vr-1 receptor, discovered in 1977, when 
stimulated, provokes the inflow of extracellular Ca
++ in re-
sponse to the loss of intracellular Ca
++ [44].  
  Vanilloid receptor VR-1 is a non selective receptor-
channel, which can be activated by protons as well as by 
capsaicin-like substances with a simil-lipidic structure, pro-
ducing the release of inflammation mediators with pain; 
moreover it is able to transduce also heath stimuli in noci-
ceptive.sensations. Capsaicin-sensitive neurons have a small 
diameter (A-delta and C fibres) and are peptidergic, releasing 
CGRP and substance P through a Ca
++ - dependent mecha-
nism, not only at the peripheral level but also centrally, in 
spinal endings of primary sensory neurons [45]. Therefore 
they can exert either peripherally or centrally both the anal-
gesic or algesic effects on nociception, sustained by opposite 
modifications of Ca
++ intracellular content [46]. Ethanol po-
tentiates VR-1 nociceptive response [47].  
  It is not yet possible to argue whether such a mechanism 
could or not be involved in the neurogenic inflammation 
process, validating in the first case Moskowitz’s theory [14].  
  Another class of receptors, named PAR (Protease Acti-
vated Receptors) has been isolated in the rat, by means of 
immunohistochemical techniques [48], in capsaicin-sensitive 
primary sensory neurons, at the level of trigeminal and spinal 
dorsal root ganglia, where they are colocated with VR-1 re-
ceptors, being probably involved also in primary headache 
pathogenetic mechanisms. 
  The PAR-2 receptor [49] is selectively activated by 
SLIGRL and SLIGKV peptides, trypsin and tryptase, prote-
ases abundantly contained in mast cells and released by them 
Table  1.  Receptors Present at the Level of Sensory Primary Neurons and Possible Effects on the Release of Neuropeptides   
Involved in Neurogenic Inflammation and Migraine Pain 
 
RECEPTORS  LIGANDS  ACTIVITY ON THE SENSORY PRIMARY NEURON 
5-HT1-D SEROTONIN    DECREASED RELEASE OF CGRP AND SUBSTANCE P 
GABA-A GABA    DECREASED RELEASE OF CGRP AND SUBSTANCE P 
CB-1   ANANDAMIDE*   DECREASED RELEASE OF CGRP AND SUBSTANCE P 
VR-1 CAPSAICIN  OR 
ANANDAMIDE** 
 INCREASED RELEASE OF CGRP AND SUBSTANCE P  
PAR-2 PEPTIDIC  CHAINS 
SLIGRL AND SLIGKV 
 INCREASED RELEASE OF CGRP AND SUBSTANCE P 
*At nanomolar concentrations. 
**At micromolar concentrations. Migraine  The Open Neurology Journal, 2009, Volume 3    69 
in course of the inflammatory process; in many tissues mast 
cells are in close contact with the endings of capsaicin-
sensitive primary sensory neurons containing neuropeptides. 
The activation of PAR-2 provokes Ca
++ mobilization and 
CGRP and substance P release in slices of rat isolated neu-
rons or vascular intracranial structures cultured in vitro, 
while in vivo the swelling CGRP-induced of the rat paw is 
observed. 
  Therefore CB, VR and PAR receptors with their ligands 
seem worthy of attention in the study of pain pathophysiol-
ogy and therapeutical problems related to the migraine [50-
53]. 
CONCLUSIONS 
  The complexity of interactions taking place in the sen-
sory neuronal network with the mediation of all different 
neurotransmitters involved gives the measure of the extreme 
difficulty connected with the knowledge of migraine patho-
genesis. Many theories have been formulated in these last 
sixty years about the pathogenesis of migraine and other 
forms of primary headache, but the problem is still far to be 
fully clarified.  
  The first theory, conceived by Wolff in 1948 [54], is 
build up on a vascular basis, considering three main aspects: 
a) during the migraine attack extra-cranial vessels dilate and 
are throbbing in a large percent of patients; b) the stimulation 
of intra-cranial vessels provokes an ipsilateral headache; c) 
vasoconstrictor drugs, like ergot derivatives, show a curative 
effect, while vasodilators, like nitrates, may induce an attack. 
On this observations he hypothesized that an intra-cranial 
vasoconstriction could be responsible of the migraine aura 
and of the following hyperemic reaction associated to local 
vasodilatation, with consecutive activation of perivascular 
nociceptive endings. Ten years later Heyck [55] completed 
the theory adding the concept that during the attack arterio-
venous anastomoses were closed, explaining in this way the 
decreased oxygen extraction observed in the symptomatic 
side. 
  Successive theories were underlining the importance of 
vasoactive and neuroactive substances (as plasmatic kinins, 
endorphins, serotonin, histamine, fatty acids, adenosine, 
prostaglandins, NO and endothelin-1), released in perivascu-
lar areas, to which could be attributed the responsibility of 
the neurogenic inflammation and its symptoms [56-59]. 
  The already mentioned theory of Moskowitz [14] was 
synthesizing in an appreciable way all theories till now ex-
posed, with the idea of the neurogenic inflammation in the 
trigemino-vascular area and the integration in the cerebral 
cortex of the painful information.  
  Another possibility to interpret the migraine pain is pro-
posed on the basis of a depression of the cortical electrical 
activity similar to the spreading depression observed in ani-
mal experimental models by Leao longtime ago [60] and 
consisting in the production of cortical hyperexcitation 
waves followed by the electrical activity suppression after 
chemical or mechanic stimuli, this last progressing by conti-
guity within the cerebral structures in posterior-anterior di-
rection, at a speed of 2-5 mm/min [61]. The spreading de-
pression can be considered, according to Olesen [62], the 
pathophysiological substrate of the migraine aura, during 
which it has been observed with the technique of xenon 133 
a decreased cerebral blood perfusion specially in the occipi-
tal area, lasting about an hour. These data have been vali-
dated by means of magneto-EEG, SPECT, MRI and PET 
studies [63], specially for the migraine with aura and, at least 
partially, also for the migraine without aura. Mitochondrial 
alterations and a decrease in Mg++ blood levels [64] have 
also been associated to migraine in neuroimaging investiga-
tions [65]. 
  Lance [66], Diener and May [67], and Welch [68] have 
proposed to consider the participation in the migraine patho-
genesis of orbital, frontal and limbic cortical areas and brain-
stem structures specialized in controlling pain mechanisms , 
like trigeminal nucleus caudalis, locus coeruleus, raphe nuc-
cleus dorsalis,, PAG and area postrema, interacting with sev-
eral neurotransmitters as noradrenaline, serotonin, dopamine 
and others, which could be “migraine generators”.  
  About the cluster headache, among other theories, it 
seems worthy of interest the immunological theory, dealing 
mostly with interleukins and cytokines receptors and involv-
ing the complex relationships between neuro-psychic, endo-
crine and immunological systems [69], as it is demonstrated 
by the reduced response of cortisol to meta-chlorophenyl-
piperazine [70]. During the attack there is the activation of 
the hypothalamic grey ipsilateral to the side affected [71]. 
  As far as tension migraine episodic and chronic, is con-
cerned, it is not clear at all whether its pathogenesis is simi-
lar or different, and in what extent, in respect to that of mi-
graine, but many resemblances have been recognised. The 
influence of stress and of protracted muscular contraction 
has been largely investigated as well as immunological im-
plications, specially in the autoimmune sense [72].  
  It is necessary to assess the importance of genetic factors 
in the pathogenesis of headache and headache pain [73]. 
  Finally, it can not be omitted that the knowledge of mi-
graine pathophysiology has significantly improved because 
of the advances realised by clinical pharmacology studies, 
from which further and ever more important insights in the 
field likely are going to be reached in a next future.  
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